A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study with PRN BID and Fixed, Dosing Regimens Alosetron in Female Subjects with Severe Diarrhea-Perdominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy